NasdaqCM - Delayed Quote USD

Kiora Pharmaceuticals, Inc. (KPRX)

3.2500
-0.0200
(-0.61%)
At close: May 9 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
16,000
16,000
0
0
0
Operating Expense
10,419.1810
10,419.1810
8,690.1830
11,726.9180
10,673.9130
Operating Income
5,580.8190
5,580.8190
-8,690.1830
-11,726.9180
-10,673.9130
Net Non Operating Interest Income Expense
1,231.4030
1,231.4030
162.8570
48.2920
-5.7100
Other Income Expense
-1,152.4840
-1,152.4840
-3,896.2510
-2,017.9940
-3,283.6650
Pretax Income
5,659.7380
5,659.7380
-12,423.5770
-13,696.6200
-13,963.2880
Tax Provision
2,065.0050
2,065.0050
90.3190
-113.0100
-192.6030
Net Income Common Stockholders
3,594.7330
3,594.7330
-13,044.8810
-13,583.6100
-13,770.6850
Diluted NI Available to Com Stockholders
3,594.7330
3,594.7330
-13,044.8810
-13,583.6100
-13,770.6850
Basic EPS
1.22
0.93
-24.25
-166.95
-514.08
Diluted EPS
1.05
0.87
-24.25
-166.95
-514.08
Basic Average Shares
3,027.0920
3,872.6440
538.0070
81.3660
26.7880
Diluted Average Shares
3,278.6520
4,125.0750
538.0070
81.3660
26.7880
Total Operating Income as Reported
4,510.2880
4,510.2880
-12,586.8960
-12,309.5230
-14,235.7680
Total Expenses
10,419.1810
10,419.1810
8,690.1830
11,726.9180
10,673.9130
Net Income from Continuing & Discontinued Operation
3,594.7330
3,594.7330
-12,513.8960
-13,583.6100
-13,770.6850
Normalized Income
4,343.2832
4,343.2832
-9,413.0733
-11,637.2136
-10,532.3346
Interest Income
1,252.8490
1,252.8490
173.9890
56.8910
1.1410
Interest Expense
21.4460
21.4460
11.1320
8.5990
6.8510
Net Interest Income
1,231.4030
1,231.4030
162.8570
48.2920
-5.7100
EBIT
5,681.1840
5,681.1840
-12,412.4450
-13,688.0210
-13,956.4370
EBITDA
5,700.3890
5,700.3890
-12,360.6470
-13,646.4120
-13,911.1410
Reconciled Depreciation
19.2050
19.2050
51.7980
41.6090
45.2960
Net Income from Continuing Operation Net Minority Interest
3,594.7330
3,594.7330
-12,513.8960
-13,583.6100
-13,770.6850
Total Unusual Items Excluding Goodwill
-1,178.5570
-1,178.5570
-3,925.0920
-2,003.4960
-3,283.6650
Total Unusual Items
-1,178.5570
-1,178.5570
-3,925.0920
-2,003.4960
-3,283.6650
Normalized EBITDA
6,878.9460
6,878.9460
-8,435.5550
-11,642.9160
-10,627.4760
Tax Rate for Calcs
0.0004
0.0004
0.0002
0
0
Tax Effect of Unusual Items
-430.0068
-430.0068
-824.2693
-57.0996
-45.3146
12/31/2021 - 2/13/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PALI Palisade Bio, Inc.
0.7546
-1.35%
 
QNRX Quoin Pharmaceuticals, Ltd.
6.19
-3.43%
 
REVB Revelation Biosciences, Inc.
3.1781
+2.85%
 
VRAX Virax Biolabs Group Limited
1.0500
-0.94%
 
PXMD PaxMedica, Inc.
0.0001
0.00%
 
XBIO Xenetic Biosciences, Inc.
3.0600
-2.86%
 
BDRX Biodexa Pharmaceuticals Plc
1.4100
+0.71%
 
YMAB Y-mAbs Therapeutics, Inc.
3.8900
-3.71%
 
DRMA Dermata Therapeutics, Inc.
0.8103
+0.04%
 
GBIO Generation Bio Co.
0.3600
+0.06%